Provided by Tiger Fintech (Singapore) Pte. Ltd.

Atossa Genetics

0.8554
+0.01241.47%
Post-market: 0.8553-0.0001-0.01%19:55 EDT
Volume:528.15K
Turnover:455.20K
Market Cap:110.49M
PE:-4.22
High:0.8999
Open:0.8430
Low:0.8430
Close:0.8430
Loading ...

Atossa Therapeutics - Will Not Be Pursuing an Appeal From Ptab Decision

THOMSON REUTERS
·
30 Jan

Atossa Therapeutics - Responds to Ptab Ruling on U.S. Patent No. 11,572,334 and Announces Issuance of U.S. Patent No. 12,201,591

THOMSON REUTERS
·
30 Jan

Atossa Therapeutics - Decision Has No Impact on Formulations Currently in Clinical Development

THOMSON REUTERS
·
30 Jan

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025

THOMSON REUTERS
·
23 Jan

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025

GlobeNewswire
·
23 Jan

BRIEF-Atos estimates year-end liquidity at EUR 2.19 billion

Reuters
·
21 Jan

TCMD Stock Rises 20% in Three Months: Should You Buy, Hold or Sell?

Zacks
·
31 Dec 2024

Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?

Zacks
·
20 Dec 2024

Atossa Therapeutics to present poster on Z-endoxifen at SABCS

TipRanks
·
13 Dec 2024

Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium

GlobeNewswire
·
12 Dec 2024

Atossa Therapeutics: 2 Mg Dose Was Associated With Higher Rates of Hot Flashes, Night Sweats and Vaginal Discharge

THOMSON REUTERS
·
11 Dec 2024

Atossa Therapeutics: No Significant Differences in Adverse Events Were Observed Between 1 Mg Dose and Placebo

THOMSON REUTERS
·
11 Dec 2024

Atossa Therapeutics Announces Full Results From Phase 2 Karisma-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density

THOMSON REUTERS
·
11 Dec 2024

Atossa Therapeutics - 1 Mg Dose Reduced Mbd by 17.3 Percentage Points, 2 Mg Dose by 23.5 VS Minimal Change in Placebo Group of 0.27

THOMSON REUTERS
·
11 Dec 2024

Atossa Therapeutics Inc - 1 Mg Dose (Z)-Endoxifen Shows Potential as Preventative Breast Cancer Therapy

THOMSON REUTERS
·
11 Dec 2024

Atossa Therapeutics' Breast Cancer Treatment Demonstrates Tumor Suppression

MT Newswires Live
·
11 Dec 2024

Atossa Therapeutics Presents Data from Study Investigating Anti-Cancer Activity of (Z)-Endoxifen-Related Compounds at AACR Special Conference in Cancer Research

GlobeNewswire
·
09 Dec 2024

Atossa Therapeutics Is Maintained at Buy by Ascendiant Capital

Dow Jones
·
09 Dec 2024

Atossa Therapeutics announces five abstracts on Z-endoxifen

TIPRANKS
·
20 Nov 2024

BRIEF-Atossa Therapeutics- Enters Open Market Sale Agreement To Sell Shares Of Common Stock Of Up To $100 Million From Time To Time - SEC Filing

Reuters
·
20 Nov 2024